DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
DIMETHYLAMINOETHANOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DIMETHYLAMINOETHANOL
×
Maximum Phase:
2
First Approval:
None
UNII:
2N6K9DRA24
Molecule Type:
Small molecule
Molecular Formula:
C4H11NO
Molecular Weight:
89.14
AlogP:
-0.46
PSA:
23.47
HBD:
1.0
HBA:
#RotB:
2.0
Source:
KOS-1584
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Tubulin stabiliser
KOS-1584
×
Maximum Phase:
2
First Approval:
None
UNII:
82481G197K
Molecule Type:
Small molecule
Molecular Formula:
C27H39NO5S
Molecular Weight:
489.68
AlogP:
5.04
PSA:
96.72
HBD:
2.0
HBA:
#RotB:
2.0
Source:
L-SULFORAPHANE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
L-SULFORAPHANE
×
Maximum Phase:
2
First Approval:
None
UNII:
7J94TPZ10L
Molecule Type:
Small molecule
Molecular Formula:
C6H11NOS2
Molecular Weight:
177.29
AlogP:
1.25
PSA:
29.43
HBD:
0.0
HBA:
#RotB:
5.0
Source:
APRICOXIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Cyclooxygenase-2 inhibitor
APRICOXIB
×
Maximum Phase:
2
First Approval:
None
UNII:
5X5HB3VZ3Z
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O3S
Molecular Weight:
356.45
AlogP:
3.5
PSA:
74.32
HBD:
1.0
HBA:
#RotB:
5.0
Source:
BLARCAMESINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BLARCAMESINE
×
Maximum Phase:
2
First Approval:
None
UNII:
9T210MMZ3F
Molecule Type:
Small molecule
Molecular Formula:
C19H23NO
Molecular Weight:
281.4
AlogP:
3.53
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
4.0
Source:
ALVELESTAT
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Severe Acute Respiratory Syndrome; Bronchiectasis; Cystic Fibrosis; Pulmonary Disease, Chronic Obstructive
Unknown
ALVELESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
6Y5629322X
Molecule Type:
Small molecule
Molecular Formula:
C25H22F3N5O4S
Molecular Weight:
545.54
AlogP:
3.29
PSA:
115.95
HBD:
1.0
HBA:
#RotB:
6.0
Source:
CP-724714
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasm Metastasis
Receptor protein-tyrosine kinase erbB-2 inhibitor
CP-724714
×
Maximum Phase:
2
First Approval:
None
UNII:
I05QZ0S4V3
Molecule Type:
Small molecule
Molecular Formula:
C27H27N5O3
Molecular Weight:
469.55
AlogP:
4.95
PSA:
98.26
HBD:
2.0
HBA:
#RotB:
9.0
Source:
ORNITHINE PHENYLACETATE
2
Small molecule
Investigational
Unknown
Unknown
Liver Cirrhosis; Liver Failure, Acute
Unknown
ORNITHINE PHENYLACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
9D6YZ105SN
Molecule Type:
Small molecule
Molecular Formula:
C13H20N2O4
Molecular Weight:
268.31
AlogP:
-0.86
PSA:
89.34
HBD:
3.0
HBA:
#RotB:
4.0
Source:
ERTEBEREL
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Hyperplasia; Schizophrenia
Estrogen receptor beta agonist
ERTEBEREL
×
Maximum Phase:
2
First Approval:
None
UNII:
2ZUL6758TZ
Molecule Type:
Small molecule
Molecular Formula:
C18H18O3
Molecular Weight:
282.34
AlogP:
4.12
PSA:
49.69
HBD:
2.0
HBA:
#RotB:
1.0
Source:
BCX-1777
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BCX-1777
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FENEBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Urticaria; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive
Tyrosine-protein kinase BTK inhibitor
FENEBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
E9L2885WUL
Molecule Type:
Small molecule
Molecular Formula:
C37H44N8O4
Molecular Weight:
664.81
AlogP:
3.57
PSA:
120.99
HBD:
2.0
HBA:
#RotB:
7.0
Source:
EVT-101
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
EVT-101
×
Maximum Phase:
2
First Approval:
None
UNII:
B55T45AA8F
Molecule Type:
Small molecule
Molecular Formula:
C16H15Cl2F3N4
Molecular Weight:
391.22
AlogP:
3.77
PSA:
43.6
HBD:
0.0
HBA:
#RotB:
4.0
Source:
OLMUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
OLMUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
CHL9B67L95
Molecule Type:
Small molecule
Molecular Formula:
C26H26N6O2S
Molecular Weight:
486.6
AlogP:
5.1
PSA:
82.62
HBD:
2.0
HBA:
#RotB:
7.0
Source:
VALEMETOSTAT TOSYLATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia-Lymphoma, Adult T-Cell; Lymphoma
Unknown
VALEMETOSTAT TOSYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
6N79I7X5II
Molecule Type:
Small molecule
Molecular Formula:
C33H42ClN3O7S
Molecular Weight:
660.23
AlogP:
4.49
PSA:
83.66
HBD:
2.0
HBA:
#RotB:
5.0
Source:
RIVIPANSEL SODIUM
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell
Unknown
RIVIPANSEL SODIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
11AEN6VWDN
Molecule Type:
Small molecule
Molecular Formula:
C58H70N6Na4O31S3
Molecular Weight:
1535.37
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
SAR-125844
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Hepatocyte growth factor receptor inhibitor
SAR-125844
×
Maximum Phase:
2
First Approval:
None
UNII:
XH93U6NIJE
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FARAMPATOR
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Schizophrenia
Glutamate receptor ionotropic AMPA positive allosteric modulator
FARAMPATOR
×
Maximum Phase:
2
First Approval:
None
UNII:
7X6P5N8K2L
Molecule Type:
Small molecule
Molecular Formula:
C12H13N3O2
Molecular Weight:
231.25
AlogP:
1.85
PSA:
59.23
HBD:
0.0
HBA:
#RotB:
1.0
Source:
LERSIVIRINE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
LERSIVIRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
R3ZGC15A9A
Molecule Type:
Small molecule
Molecular Formula:
C17H18N4O2
Molecular Weight:
310.36
AlogP:
2.54
PSA:
94.86
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PER977
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PER977
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
POZANICLINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Attention Deficit Disorder with Hyperactivity; Tobacco Use Disorder
Neuronal acetylcholine receptor; alpha6/beta2 partial agonist
POZANICLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
CL2002R563
Molecule Type:
Small molecule
Molecular Formula:
C11H16N2O
Molecular Weight:
192.26
AlogP:
1.52
PSA:
34.15
HBD:
1.0
HBA:
#RotB:
3.0
Source:
PYRUVATE
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Prostatic Neoplasms
Unknown
PYRUVATE
×
Maximum Phase:
2
First Approval:
None
UNII:
8558G7RUTR
Molecule Type:
Small molecule
Molecular Formula:
C3H4O3
Molecular Weight:
88.06
AlogP:
-0.34
PSA:
54.37
HBD:
1.0
HBA:
#RotB:
1.0
Source:
PF-03654746
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Schizophrenia; Attention Deficit Disorder with Hyperactivity; Rhinitis, Allergic, Seasonal; Tourette Syndrome
Histamine H3 receptor antagonist
PF-03654746
×
Maximum Phase:
2
First Approval:
None
UNII:
G3QE979K1X
Molecule Type:
Small molecule
Molecular Formula:
C18H24F2N2O
Molecular Weight:
322.4
AlogP:
3.13
PSA:
32.34
HBD:
1.0
HBA:
#RotB:
5.0
Source:
DNK333
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic; Irritable Bowel Syndrome
Neurokinin 1 receptor antagonist
DNK333
×
Maximum Phase:
2
First Approval:
None
UNII:
G9BL4978MZ
Molecule Type:
Small molecule
Molecular Formula:
C27H25Cl2F6N3O3
Molecular Weight:
624.41
AlogP:
6.06
PSA:
78.51
HBD:
2.0
HBA:
#RotB:
7.0
Source:
LUMICITABINE
2
Small molecule
Investigational
Unknown
Unknown
Respiratory Syncytial Virus Infections
RNA-directed RNA polymerase L inhibitor
LUMICITABINE
×
Maximum Phase:
2
First Approval:
None
UNII:
BNW5PQ52G1
Molecule Type:
Small molecule
Molecular Formula:
C18H25ClFN3O6
Molecular Weight:
433.86
AlogP:
1.44
PSA:
122.74
HBD:
1.0
HBA:
#RotB:
7.0
Source:
PHOSPHOCREATINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PHOSPHOCREATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-0773
2
Small molecule
Investigational
Unknown
Unknown
Sarcopenia
Androgen Receptor modulator
MK-0773
×
Maximum Phase:
2
First Approval:
None
UNII:
5730VNW22X
Molecule Type:
Small molecule
Molecular Formula:
C27H34FN5O2
Molecular Weight:
479.6
AlogP:
4.13
PSA:
90.98
HBD:
2.0
HBA:
#RotB:
3.0
Source:
ACALISIB
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms
PI3-kinase p110-delta subunit inhibitor
ACALISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
OVW60IDW1D
Molecule Type:
Small molecule
Molecular Formula:
C21H16FN7O
Molecular Weight:
401.41
AlogP:
3.36
PSA:
101.38
HBD:
2.0
HBA:
#RotB:
4.0
Source:
DORAMAPIMOD
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis
MAP kinase p38 alpha inhibitor
DORAMAPIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
HO1A8B3YVV
Molecule Type:
Small molecule
Molecular Formula:
C31H37N5O3
Molecular Weight:
527.67
AlogP:
5.99
PSA:
80.65
HBD:
2.0
HBA:
#RotB:
7.0
Source:
MERIMEPODIB
2
Small molecule
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Inosine-5'-monophosphate dehydrogenase 1 inhibitor
MERIMEPODIB
×
Maximum Phase:
2
First Approval:
None
UNII:
2ZL2BA06FU
Molecule Type:
Small molecule
Molecular Formula:
C23H24N4O6
Molecular Weight:
452.47
AlogP:
4.01
PSA:
123.95
HBD:
3.0
HBA:
#RotB:
7.0
Source:
PRALICIGUAT
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure
Soluble guanylate cyclase activator
PRALICIGUAT
×
Maximum Phase:
2
First Approval:
None
UNII:
R1S0H458SA
Molecule Type:
Small molecule
Molecular Formula:
C21H14F8N6O2
Molecular Weight:
534.37
AlogP:
4.59
PSA:
101.89
HBD:
2.0
HBA:
#RotB:
7.0
Source:
LCL-161
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis
Unknown
LCL-161
×
Maximum Phase:
2
First Approval:
None
UNII:
6TNS415Y3P
Molecule Type:
Small molecule
Molecular Formula:
C26H33FN4O3S
Molecular Weight:
500.64
AlogP:
3.85
PSA:
91.4
HBD:
2.0
HBA:
#RotB:
8.0
Source:
IRSENONTRINE
2
Small molecule
Investigational
Unknown
Unknown
Dementia
Unknown
IRSENONTRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H22N4O3
Molecular Weight:
390.44
AlogP:
3.53
PSA:
82.03
HBD:
1.0
HBA:
#RotB:
3.0
Source:
EKB-569
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EKB-569
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FGF401
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular
Fibroblast growth factor receptor 4 inhibitor
FGF401
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALDUMASTAT
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis
Unknown
ALDUMASTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C20H24F2N4O3
Molecular Weight:
406.43
AlogP:
1.77
PSA:
81.75
HBD:
2.0
HBA:
#RotB:
5.0
Source:
1
2
…
116
117
118
119
120
121
122
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA